American Society of Hematology

Morning Symposia

Friday, December 8, 7:00 a.m. - 11:00 a.m.

Advances in the Management of Chronic Lymphocytic Leukemia and Other B-Cell Lymphomas

Register now

This program is sponsored by North American Center for Continuing Medical Education and supported by Teva Pharmaceuticals.

Location: Atlanta Marriott Marquis
Room: A703-A704

A multidisciplinary panel of experts will convene to provide the latest clinical evidence on newer/emerging treatment used to overcome challenges within the management of CLL and other B-cell lymphomas.

Program Chair
Chadi Nabhan, MD, MBA, FACP, Cardinal Health Specialty Solutions, Chicago, IL

Speakers

  • Matthew J. Matasar, MD, MS, Memorial Sloan-Kettering Cancer Center, New York, NY, Department of Medicine, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY
  • Anthony R. Mato, MD, University of Pennsylvania, Philadelphia, PA
  • Val R. Adams, PharmD, FCCP, BCOP, University of Kentucky, Lexington, KY
  • Barbara B. Rogers, CRNP, MN, AOCN, ANP-BC, Fox Chase Cancer Center, Philadelphia, PA

Contact
Jennifer Browne
609-630-6204
jbrowne@naccme.com

back to top

Evidence- And Value-Based Approaches to Pathology and Laboratory Diagnosis and Prognosis of Common Hematologic Neoplasms: A Case-Based Illustration

Register now

This program is sponsored and supported by Mayo Clinic.

Location: Atlanta Marriott Marquis
Room: Atrium A

The recent advancements in the laboratory diagnosis and prognostication of hematologic neoplasms have created a knowledge gap for many practicing hematologists/oncologists and hematopathologists. This program’s overall objective is to update the practicing hematologists/oncologists and hematopathologists about the evolving repertoire of test options and appropriate testing strategies.

We aim to inform participants on the most cost-effective, diagnostically efficient testing strategies in the evaluation of hematologic malignancies. Using data-driven testing algorithms derived from the Mayo Clinic Hematopathology/Hematology practice and available literature, we will illustrate how unnecessary, redundant, and costly laboratory tests can be eliminated from the participants’ practices while maintaining the highest quality medical care.

Program Chair
Rajiv K. Pruthi, MBBS, Mayo Clinic, Rochester, MN

Speakers

  • Francis K Buadi, MD, Mayo Clinic, Rochester, MN
  • Dragan Jevremovic, MD PhD, Mayo Clinic, Rochester, MN
  • Ellen D. McPhail, MD, Mayo Clinic, Rochester, MN
  • Mrinal M Patnaik, MBBS, Mayo Clinic, Rochester, MN
  • Kaaren K. Reichard, MD, Mayo Clinic, Rochester, MN
  • David S Viswanatha, MD, Mayo Clinic, Rochester, MN

Contact
Sharon Preuss
Mayo Clinic
507-284-8742
preuss.sharon@mayo.edu

back to top

Improving MDS Outcomes from Diagnosis to Treatment: A Multidisciplinary Approach

Register now

This program is sponsored by The France Foundation in collaboration with the American Society of Pathology and supported by Celgene Corporation, American Society for Clinical Pathology.

Location: Georgia World Congress Center
Room: A402-403

This award winning, dynamic session offers participants a unique opportunity to learn from a multidisciplinary team of experts in hematology, oncology and hematopathology. Learners will make clinical decisions with the faculty as they review real life cases during this highly interactive and engaging activity.

Program Chair
Amy E. DeZern, MD, Johns Hopkins University, Baltimore, MD

Speakers

  • Steven D. Gore, MD, Yale School of Medicine, New Haven, CT
  • Dita Gratzinger, MD, PhD, Stanford University School of Medicine, Stanford, CA
  • Marilyn L. Slovak, PhD, FACMG, University of New Mexico TriCore Reference Laboratories, Albuquerque, NM

Contact
Amanda Noe, The France Foundation
860-598-2282
ANoe@francefoundation.com

back to top

Individualizing Therapeutic Strategies for Patients with MDS

Register now

This program is sponsored and supported by MDS Foundation, Inc.

Location: Georgia World Congress Center
Room: B308-309

Recent developments in our knowledge of the immune system, the bone marrow micro-environment and the genetic evolution of MDS are optimizing prognostication and management strategies. Intrinsic and extrinsic factors contributing to disease pathogenesis and influencing therapeutic response will be discussed.

Program Chairs

  • Rena Buckstein, MD, Odette Cancer Center, Toronto, ON
  • Mario Cazzola, MD, Fondazione IRCCS Policlinico San Matteo & University of Pavia, Pavia

Speakers

  • Jude Fitzgibbon, PhD, Queen Mary University of London, London
  • Rami Komrokji, MD, Moffitt Cancer Center, Tampa, FL
  • Shahram Kordasti, MD, PhD, King's College Hospital and King's College London, London
  • John Koreth, MD, PhD, Dana-Farber Cancer Institute, Boston, MA
  • Luca Malcovati, MD, University of Pavia Medical School, Piazzale Golgi 2

Contact
Lea Harrison
MDS Foundation, Inc.
609-298-1600 ext. 201
lharrison@mds-foundation.org

back to top

Integrating Therapeutic Advances to Improve Current Practices in Myeloma Patient Care

Register now

This program is sponsored by Penn State College of Medicine and supported by the Multiple Myeloma Research Foundation.

Location: Georgia World Congress Center
Room: Murphy Ballroom 1-2

The clinical multiple myeloma (MM) arena has undergone significant advancement in recent years—not only in terms of available treatments but also in diagnosis and staging, minimal residual disease monitoring, and supportive care. This expansion of treatment options brings both opportunities and challenges. Although recent advances in MM treatment have led to improved median survival, the success has not been uniform. Some patients enjoy many years in clinical remission, whereas others have a poor prognosis with survival of only 2 or 3 years. This observation speaks to the heterogeneity of MM and the inappropriateness of a one-size-fits-all approach. Improving patient outcomes requires building on the foundation of current myeloma therapies with new agents and combinations, and it requires improving the understanding of the nature of the disease to provide patients with a more personalized approach to treatment.

This symposium will consist of a series of evidence-based presentations and interactive patient-based video vignettes designed to stimulate audience engagement. Real-world case studies will provide an opportunity for learners to respond to practice-related issues and questions based on such factors as patient profile, clinical evidence, and assessment of risk/benefit to achieve the best possible durable response. IPad technology will also be utilized.

Program Chairs

  • Paul G. Richardson, MD, Dana-Farber Cancer Institute, Boston, MA
  • A. Stewart, MBChB, MBA, Mayo Clinic, Scottsdale, AZ

Speakers

  • Jesus G. Berdeja, MD, Sarah Cannon Research Institute, Nashville, TN
  • Nina Shah, MD, University of California San Francisco, San Francisco, CA
  • Peter M. Voorhees, MD, University of North Carolina, Chapel Hill, NC
  • Katja Weisel, MD, University Hospital of Tuebingen, Tuebingen

Contact
Karen Tenaglia
RedMedEd
609-558-7775
ktenaglia@redmeded.com

back to top

Precision and Emerging Medicine for Hematological Diseases

Register now

This program is sponsored by The Leukemia and Lymphoma Society, Postgraduate Institute for Medicine, and RMEI Medical Education, LLC, and is supported by Abbvie, Inc., Amgen, Inc., AstraZeneca Pharmaceuticals LP/Acerta Pharma, and Celgene Corporation.

Location: Georgia World Congress Center
Room: B401-B402

The Friday Satellite Symposium, “Precision and Emerging Medicine for Hematological Diseases,” will directly address the most relevant information available at the time of the presentation with regard to:

  • Technological advances in molecular techniques for the diagnosis and monitoring of hematologic malignancies
  • The latest research and development in emerging therapies for the treatment of leukemia, lymphoma, and myeloma
  • Key factors related to applying precision medicine for hematologic malignancies in clinical practice

Program Chair
Steven T. Rosen, MD, City of Hope, Duarte, CA

Speakers

  • Sandeep Dave, MD, Duke University Medical Center, Durham, NC
  • Jonathan J. Keats, PhD, Translational Genomics Research Institute, Phoenix, AZ
  • Karen L. Kaul, MD, PhD, NorthShore University HealthSystem, Evanston, IL
  • Cheryl L. Willman, MD, University of New Mexico Cancer Center, Albuquerque, NM
  • Anas Younes, MD, Memorial Sloan-Kettering Cancer Center, New York, NY
  • John Chan, MD, City of Hope, Duarte, CA

Contact
Cherie Haley
RMEI Medical Education, LLC
856-672-3262
chaley@rmei.com

back to top